Skip to main content
. 2020 May 31;9(6):1647. doi: 10.3390/jcm9061647

Table 2.

NEC patients’ characteristics.

Characteristics All Patients (n = 30)
Sex, female 12 (40%)
Age at initial diagnosis, median (years) 49 (26–71)
Comorbidities
Diabetes n = 3 (27%)
Arterial hypertension n = 3 (27%)
Primary tumor localization
Pancreas n = 14 (47%)
Ileum n = 2 (6%)
Stomach n = 7 (23%)
Other: n = 7 (23%)
Rectum n= 2
Thymus n = 1
Lung n = 1
Larynx n = 1
Cortex of suprarenal gland n = 1
CUP n = 1
Median survival (months), range n = 123 (0–176)
No. of patients alive n = 11 (37%)
No. of death patients n = 7 (23%)
No. of patients lost-to-follow-up n = 12 (40%)
Metastases n = 20
Hepatic metastases n = 20 (20/24; 83%)
Lymph node metastases n = 16 (16/25; 64%)
Bone metastases n = 6 (6/22; 27%)
Peritoneal carcinomatosis n = 7 (7/22; 32%)
Grading: n = 29
G1 n = 0
G2 n = 2 (7%)
G3 n = 25 (93%)
Ki-67 (%), median (range) 28 (20–95)
Ki-67 ≤ 20 n = 8 (36%)
Ki-67 >20 n = 14 (64%)
T stage n = 9
T1 n = 0
T2 n = 2 (22%)
T3 n= 3 (33%)
T4 n = 4 (44%)
Relapse
no n = 19 (95%)
yes n = 1 (5%)
Functional disease
no n = 16 (80%)
yes n = 4 (20%)
SSR expression n = 22
no n = 16 (73%)
yes n = 6 (27%)
Creatinine (mg/dL), median; (range) 0.85; (0.52–1.60)
Creatine < 1 n = 21 (81%)
Creatine ≥ 1 n = 5 (19%)
Chromogranin A (μg/L), median; (range) 138 (1–454)
<137 μg/L n = 4 (50%)
≥137 μg/L n = 4 (50%)

NEC, neuroendocrine carcinomas; CUP, cancer of unknown primary; SSR, somatostatin receptor.